Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04781374 |
|
Recruitment Status :
Withdrawn
(Withdrawal of funding)
First Posted : March 4, 2021
Last Update Posted : July 11, 2023
|
Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Puma Biotechnology, Inc.
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
David J. Einstein, Beth Israel Deaconess Medical Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
| Recruitment Status : | Withdrawn |
|---|---|
| Actual Primary Completion Date : | September 24, 2021 |
| Actual Study Completion Date : | September 24, 2021 |